ES2461016B1 - Method for the diagnosis and / or prognosis of morbid obesity - Google Patents

Method for the diagnosis and / or prognosis of morbid obesity Download PDF

Info

Publication number
ES2461016B1
ES2461016B1 ES201231767A ES201231767A ES2461016B1 ES 2461016 B1 ES2461016 B1 ES 2461016B1 ES 201231767 A ES201231767 A ES 201231767A ES 201231767 A ES201231767 A ES 201231767A ES 2461016 B1 ES2461016 B1 ES 2461016B1
Authority
ES
Spain
Prior art keywords
mir
prognosis
diagnosis
morbid obesity
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES201231767A
Other languages
Spanish (es)
Other versions
ES2461016A1 (en
Inventor
Francisco José ORTEGA DELGADO
Wifredo Ricart Engel
Gema FRÜHBECK MARTÍNEZ
José Manuel FERNÁNDEZ-REAL
José María MERCADER BIGAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA (IDIBGI)
Centro De Investigacion Biomedica En Red Fisiopatologia de la Obesidad Y Nutricion (ciberobn)
CT DE INVESTIGACION BIOMEDICA EN RED FISIOPATOLOGIA de la OBESIDAD Y NUTRICION CIBEROBN
INST INVESTIGACIO BIOMEDICA DE GIRONA IDIBGI
Barcelona Supercomputing Center
Universidad de Navarra
Original Assignee
INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA (IDIBGI)
Centro De Investigacion Biomedica En Red Fisiopatologia de la Obesidad Y Nutricion (ciberobn)
CT DE INVESTIGACION BIOMEDICA EN RED FISIOPATOLOGIA de la OBESIDAD Y NUTRICION CIBEROBN
INST INVESTIGACIO BIOMEDICA DE GIRONA IDIBGI
Barcelona Supercomputing Center
Universidad de Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA (IDIBGI), Centro De Investigacion Biomedica En Red Fisiopatologia de la Obesidad Y Nutricion (ciberobn), CT DE INVESTIGACION BIOMEDICA EN RED FISIOPATOLOGIA de la OBESIDAD Y NUTRICION CIBEROBN, INST INVESTIGACIO BIOMEDICA DE GIRONA IDIBGI, Barcelona Supercomputing Center, Universidad de Navarra filed Critical INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA (IDIBGI)
Priority to ES201231767A priority Critical patent/ES2461016B1/en
Publication of ES2461016A1 publication Critical patent/ES2461016A1/en
Application granted granted Critical
Publication of ES2461016B1 publication Critical patent/ES2461016B1/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método para el diagnóstico y/o pronóstico de obesidad mórbida.#La presente invención se refiere a un método in vitro para el diagnóstico y/o pronóstico de obesidad mórbida caracterizado por comprender la detección de la expresión de al menos miR-142-3p, miR-140-5p, miR-15a, miR-520c-3p, miR-423-5p, miR-222, o miR-130b o cualquiera de sus combinaciones. También se refiere al uso de los mismos como biomarcadores de dicha enfermedad, a un kit para su detección y al uso in vitro del kit para el diagnóstico y/o pronóstico de obesidad mórbida. Además también se refiere al uso de inhibidores de miR-142-3p, miRl40-5p y miR-222 para el tratamiento de obesidad mórbida y al uso de miR-520c-3p, miR-15a, miR-130b y miR-423-5p o de cualquiera de sus combinaciones para el tratamiento de dicha enfermedad.Method for the diagnosis and / or prognosis of morbid obesity. # The present invention relates to an in vitro method for the diagnosis and / or prognosis of morbid obesity characterized by comprising the detection of the expression of at least miR-142-3p, miR-140-5p, miR-15a, miR-520c-3p, miR-423-5p, miR-222, or miR-130b or any combination thereof. It also refers to their use as biomarkers of said disease, a kit for its detection and the in vitro use of the kit for the diagnosis and / or prognosis of morbid obesity. It also refers to the use of miR-142-3p, miRl40-5p and miR-222 inhibitors for the treatment of morbid obesity and the use of miR-520c-3p, miR-15a, miR-130b and miR-423- 5p or any of its combinations for the treatment of said disease.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

imagen26image26

imagen27image27

imagen28image28

imagen29image29

imagen30image30

imagen31image31

imagen32image32

imagen33image33

imagen34image34

imagen35image35

imagen36image36

imagen37image37

imagen38image38

imagen39image39

imagen40image40

imagen41image41

imagen42image42

imagen43image43

imagen44image44

imagen45image45

imagen46image46

imagen47image47

imagen48image48

imagen49image49

imagen50image50

imagen51image51

imagen52image52

imagen53image53

imagen54image54

imagen55image55

imagen56image56

imagen57image57

imagen58image58

imagen59image59

imagen60image60

Claims (1)



 imagen1image 1 imagen2image2 imagen3image3 imagen4image4 imagen5image5 imagen6image6
ES201231767A 2012-11-15 2012-11-15 Method for the diagnosis and / or prognosis of morbid obesity Withdrawn - After Issue ES2461016B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201231767A ES2461016B1 (en) 2012-11-15 2012-11-15 Method for the diagnosis and / or prognosis of morbid obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231767A ES2461016B1 (en) 2012-11-15 2012-11-15 Method for the diagnosis and / or prognosis of morbid obesity

Publications (2)

Publication Number Publication Date
ES2461016A1 ES2461016A1 (en) 2014-05-16
ES2461016B1 true ES2461016B1 (en) 2015-03-16

Family

ID=50686529

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201231767A Withdrawn - After Issue ES2461016B1 (en) 2012-11-15 2012-11-15 Method for the diagnosis and / or prognosis of morbid obesity

Country Status (1)

Country Link
ES (1) ES2461016B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130130927A1 (en) * 2010-03-11 2013-05-23 Helen Heneghan Detection and quantification of micrornas in the circulation and the use of circulating micrornas as biomarkers for cancer
US20140057838A1 (en) * 2011-04-11 2014-02-27 The Trustees Of Columbia University In The City Of New York Osteoblast-expressed lipocalin 2 regulates glucose metabolism

Also Published As

Publication number Publication date
ES2461016A1 (en) 2014-05-16

Similar Documents

Publication Publication Date Title
ES2644844T3 (en) Support mechanism
CO6821893A2 (en) Use of anti-cd19 antibody immunoconjugated with maitansinoid for the treatment of b-cell tumor symptom
CR20140034A (en) METHODS TO TREAT CANCER BY THE USE OF MEK ANCHORIST ANTAGONISTS TO THE AXIS PD-1E INHIBITORS
ES2643848T3 (en) Method to quantify UV disinfectant doses using indicators
JP2013521563A5 (en)
ES2641862T3 (en) Process for the elaboration of CCR3 inhibitors
JP2013541578A5 (en)
ES2606627T8 (en) Specific anti-CD160 antibodies for the treatment of eye disorders based on neoangiogenesis
BR112013034055A2 (en) alcaftadine for use in the treatment of urticaria
BR112014008089A2 (en) method for diagnosing alzheimer's disease, use of the method, and kit for performing the method
CO6910186A2 (en) Use of omega fatty acids for the treatment of diseases
BR112012003958A2 (en) method for producing an 1-amino acid.
BR112013032533A2 (en) flexographic printing apparatus
BR112012000258A2 (en) process for preparing an alkenone.
BRPI1008706A2 (en) device for diagnosis.
BR112013020369A2 (en) hydrophobic modified peptides for specific liver diagnosis.
ES2642085T3 (en) Anaerobic sludge treatment procedures
BRPI1007069A2 (en) Method for producing an 1-amino acid.
CO7160087A2 (en) Nalmefene to reduce alcohol consumption in specific target populations
JP2014507463A5 (en)
ES2641554T3 (en) Parts kit for surgical anchor placement
ES2414290R1 (en) METHOD FOR THE DIAGNOSIS AND / OR FORECAST OF ACUTE RENAL DANO
ES2461016B1 (en) Method for the diagnosis and / or prognosis of morbid obesity
JP2013129938A5 (en)
JP2012209496A5 (en)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2461016

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150316

FA2A Application withdrawn

Effective date: 20150728